Membrane (CD8⁺PD-1⁺ and CD4+PD-1⁺) and soluble (sPD-1 and sPD-L1) forms of immune checkpoints in melanoma, breast cancer, and oral mucosal cancer patients: A observational study
- Authors: Zabotina T.N.1, Chertkova A.I.1, Borunova A.A.1, Kushlinskii N.E.1, Gershtein E.S.1, Zakharova E.N.1, Shoua E.K.1, Tsiklauri V.T.1, Samoylenko I.V.1, Khoroshilov M.V.1, Kadagidze Z.G.1
-
Affiliations:
- Blokhin National Medical Research Center of Oncology
- Issue: Vol 25, No 3 (2023)
- Pages: 301-307
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/148896
- DOI: https://doi.org/10.26442/18151434.2023.3.202443
- ID: 148896
Cite item
Full Text
Abstract
Background. The PD-1/PD-L1 pathway plays an important role in tumor evasion from immunological surveillance. In addition to the membrane forms of PD-1 and PD-L1, there are soluble variants: sPD-1 and sPD-L1. Both membrane and soluble forms have immunoregulatory properties and can affect the function and number of different immune cell populations.
Aim. To study the relationship between the initial level of CD8⁺PD-1⁺ and CD4+PD-1⁺ lymphocytes and soluble forms of sPD-1 and sPD-L1 with the percentage of the main effector and regulatory populations of peripheral blood (PB) lymphocytes and tumor-infiltrating lymphocytes.
Materials and methods. The study included melanoma, breast cancer and the oral mucosa cancer patients. The percentage of cell populations of PB lymphocytes and tumor-infiltrating lymphocytes was determined by flow cytometry before treatment. The concentrations of sPD-1 and sPD-L1 proteins were studied in blood serum using enzyme immunoassay.
Results. The relationship of the level of CD8⁺PD-1⁺ cells with certain populations of CD8-lymphocytes in PB and tumor tissue was found. In the PB of melanoma patients with CD8⁺CD11b⁺CD28⁺ and CD8⁺CD11b⁻CD28⁻ T cells, in breast cancer patients with a population of CD8⁺CD11b⁺CD28⁺ lymphocytes. In the tumor tissue of all patients there was a positive correlation with a population of regulatory CD8⁺CD11b⁻CD28⁻ T cells. The immunoregulatory properties of sPD-1 and sPD-L1 were confirmed. Both sPD-1 and sPD-L1 levels were positively correlated with the number of suppressor CD8⁺CD11b⁻CD28⁻ T cells and negatively with the level of CD8 lymphocytes, CD8⁺CD11b⁺CD28⁺ cytotoxic/memory T cells, B cells and activated CD25 lymphocytes.
Conclusion. The results of the study can make a certain contribution to the study of the prognostic significance of membrane and soluble forms of PD-1 and PD-L1, taking into account the peculiarities of their relationship with suppressor and effector populations of lymphocytes of systemic and local immunity.
Full Text
##article.viewOnOriginalSite##About the authors
Tatiana N. Zabotina
Blokhin National Medical Research Center of Oncology
Author for correspondence.
Email: tatzabotina@yandex.ru
ORCID iD: 0000-0001-7631-5699
d. sci. (biol.)
Russian Federation, MoscowAntonina I. Chertkova
Blokhin National Medical Research Center of Oncology
Email: antcher@gmail.com
ORCID iD: 0000-0001-9146-5986
cand. sci. (med.)
Russian Federation, MoscowAnna A. Borunova
Blokhin National Medical Research Center of Oncology
Email: borunova-a@yandex.ru
ORCID iD: 0000-0002-1854-3455
cand. sci. (med.)
Russian Federation, MoscowNikolay E. Kushlinskii
Blokhin National Medical Research Center of Oncology
Email: biochimia@yandex.ru
ORCID iD: 0000-0002-3898-4127
d. sci. (med.), prof., acad. RAS
Russian Federation, MoscowElena S. Gershtein
Blokhin National Medical Research Center of Oncology
Email: esgershtein@gmail.com
ORCID iD: 0000-0002-3321-801X
d. sci. (biol.), prof.
Russian Federation, MoscowElena N. Zakharova
Blokhin National Medical Research Center of Oncology
Email: zakharovaen@yandex.ru
ORCID iD: 0000-0003-2790-6673
cand. sci. (med.)
Russian Federation, MoscowEsma K. Shoua
Blokhin National Medical Research Center of Oncology
Email: essfires@gmail.com
ORCID iD: 0000-0003-3937-474X
oncologist
Russian Federation, MoscowVasily T. Tsiklauri
Blokhin National Medical Research Center of Oncology
Email: Tvtsiklauri@yandex.ru
ORCID iD: 0000-0002-3090-695X
oncologist
Russian Federation, MoscowIgor V. Samoylenko
Blokhin National Medical Research Center of Oncology
Email: i.samoylenko@ronc.ru
ORCID iD: 0000-0001-7150-5071
cand. sci. (med.)
Russian Federation, MoscowMaxim V. Khoroshilov
Blokhin National Medical Research Center of Oncology
Email: maximkhoroshilov@gmail.com
ORCID iD: 0000-0002-3770-5173
oncologist
Russian Federation, MoscowZaira G. Kadagidze
Blokhin National Medical Research Center of Oncology
Email: kad-zaira@yandex.ru
ORCID iD: 0000-0002-0058-0987
d. sci. (med.), prof.
Russian Federation, MoscowReferences
- Кушлинский Н.Е., Фридман М.В., Морозов А.А., и др. PD-1-путь: биологическая значимость, клиническое применение и существующие проблемы. Молекулярная медицина. 2019;(1) [Kushlinskii NE, Fridman MV, Morozov AA, et al. PD-1-path: biological significance, clinical application, and existing problems. Molecular Medicine. 2019;(1) (in Russian)]. doi: 10.29296/24999490-2019-01-01
- Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: Signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33-59. doi: 10.1007/978-981-15-3266-53
- Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: Clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111-22. doi: 10.1080/21645515.2019.1571892
- Li HY, McSharry M, Bullock B, et al. The tumor microenvironment regulates sensitivity of murine lung tumors to PD-1/PD-L1 antibody blockade. Cancer Immunol Res. 2017;5(9):767-77. doi: 10.1158/2326-6066.CIR-16-0365
- Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143-58. doi: 10.1038/nrclinonc.2015.209
- Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18(4):842-59. doi: 10.1038/s41423-020-00565-9
- Solomon B, Young RJ, Bressel M, et al. Prognostic significance of PD-L1(+) and CD8(+) immune cells in HPV(+) oropharyngeal squamous cell carcinoma. Cancer Immunol Res. 2018;6(3):295-304. doi: 10.1158/2326-6066.CIR-17-0299
- Кушлинский Н.Е., Герштейн Е.С., Горячева И.О., и др. Растворимый лиганд рецептора контрольной точки иммунитета (sPD-L1) в сыворотке крови при почечно-клеточном раке. Бюллетень экспериментальной биологии и медицины. 2018;166(9):325-9 [Kushlinskii NE, Gershtein ES, Goryacheva IO, et al. Soluble ligand of the immune checkpoint receptor (sPD-L1) in blood serum of patients with renal cell carcinoma. Bulletin of Experimental Biology and Medicine. 2018;166(9):325-9 (in Russian)].
- Ковалева О.В., Грачев А.Н., Макарова Э.И., и др. Прогностическая значимость sPD-1/sPD-L1 при раке почки в зависимости от фенотипа опухолевых и стромальных клеток. Онкоурология. 2022;18(2):17-28 [Kovaleva OV, Gratchev AN, Makarova EI, et al. Prognostic significance of sPD-1/sPD-L1 in renal cancer depending on the phenotype of tumor and stromal cells. Onkourologiya = Cancer Urology. 2022;18(2):17-28 (in Russian)]. doi: 10.17650/1726-9776-2022-18-2-17-28
- Li X, Zheng Y, Yue F. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in various cancers: A meta-analysis. Target Oncol. 2021;16(1):13-26. doi: 10.1007/s11523-020-00763-5
- Ruan Y, Hu W, Li W, et al. Analysis of plasma EBV-DNA and soluble checkpoint proteins in nasopharyngeal carcinoma patients after definitive intensity-modulated radiotherapy. BioMed Res Int. 2019;2019:3939720. doi: 10.1155/2019/3939720
- Sorensen SF, Demuth C, Weber B, et al. Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. Lung Cancer. 2016;100:77-84. doi: 10.1016/j.lungcan.2016.08.001
- Bian B, Fanale D, Dusetti N, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019;8(4):e1561120. doi: 10.1080/2162402x.2018.1561120
- Xing YF, Zhang ZL, Shi MH, et al. The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(2):102-6 (in Chinese). PMID: 22455965
- Shi MH, Xing YF, Zhang ZL, et al. Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes. Zhonghua Zhong Liu Za Zhi. 2013;35(2):85-8 (in Chinese). doi: 10.3760/cma.j.issn.0253-3766.2013.02.002
- Заботина Т.Н., Черткова А.И., Борунова А.А., и др. Взаимосвязь субпопуляций лимфоцитов больных раком молочной железы с результатами лечения. Российский биотерапевтический журнал. 2021;20(3):25-33 [Zabotina TN, Chertkova AI, Borunova AA, et al. Relationship of lymphocyte subpopulations in breast cancer patients with treatment results. Rossiyskiy bioterapevticheskiy zurnal = Russian Journal of Biotherapy. 2021;20(3):25-33 (in Russian)]. doi: 10.17650/1726-9784-2021-20-3-25-33
- Fiorentini S, Licenziati S, Alessandri G, et al. CD11b expression identifies CD8+CD28+ T lymphocytes with phenotype and function of both naive/memory and effector cells. J Immunol. 2001;166(2):900-7. doi: 10.4049/jimmunol.166.2.900
- Caruso A, Fiorentini S, Licenziati S, et al. Expansion of rare CD8+ CD28- CD11b- T cells with impaired effector functions in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2000;24(5):465-74. doi: 10.1097/00126334-200008150-00012
- Freedman MS, Ruijs TC, Blain M, Antel JP. Phenotypic and functional characteristics of activated CD8+ cells: a CD11b-CD28- subset mediates noncytolytic functional suppression. Clin Immunol Immunopathol. 1991;60(2):254-67. doi: 10.1016/0090-1229(91)90068-l
- Beltra JC, Manne S, Abdel-Hakeem MS, et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. EJ Immunity. 2020;52(5):825-41. doi: 10.1016/j.immuni.2020.04.014
- Schnell A, Schmidl C, Herr W, Siska PJ. The peripheral and intratumoral immune cell landscape in cancer patients: a proxy fort biology and a tool for outcome prediction. Biomedicines. 2018;6(1):25. doi: 10.3390/biomedicines6010025
- Cillo AR, Kürten CHL, Tabib T, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52(1):183-99.e9. doi: 10.1016/j.immuni.2019.11.014
- Garaud S, Buisseret L, Solinas C, et al. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 2019;5(18):e129641. doi: 10.1172/jci.insight.129641
- Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549-55. doi: 10.1038/s41586-019-1922-8
- Кадагидзе З.Г., Черткова А.И., Заботина Т.Н., и др. Взаимосвязь маркеров ранней и поздней активации лимфоцитов с эффективностью неоадъювантной химиотерапии больных трижды негативным раком молочной железы. Иммунология. 2021;42(2):112-24 [Kadagidze ZG, Chertkova AI, Zabotina TN, et al. The relationship of markers of early and late lymphocytes activation with the effectiveness of neoadjuvant chemotherapy in patients with triple negative breast cancer with the effi ciency of neoadjuvant chemotherapy in triple negative breast cancer patients. Immunologiya = Immunology. 2021;42(2):112-24 (in Russian)]. doi: 10.33029/0206-4952-2021-42-2-112-124
- McFarland HI, Nahill SR, Maciaszek JW, Welsh RM. CD11b (Mac-1): A marker for CD8+ cytotoxic T cell activation and memory in virus infection. J Immunol. 1992;149(4):1326-3310. PMID: 1500720
- Christensen JE, Andreasen SO, Christensen JP, Thomsen AR. CD11b expression as a marker to distinguish between recently activated effector CD8(+) T cells and memory cells. Int Immunol. 2001;13(4):593-600. doi: 10.1093/intimm/13.4.593
- Marzagalli M, Ebelt ND, Manuel ER. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin Cancer Biol. 2019;59:236-50. doi: 10.1016/j.semcancer.2019.08.002